{"id":"W4411535590","doi":"10.1080/14796678.2025.2513805","title":"Long-term safety and effectiveness of evinacumab in people with homozygous familial hypercholesterolemia: a plain language summary","year":2025,"lang":"en","type":"article","venue":"Future Cardiology","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université du Québec à Chicoutimi","funders":"Servier; Novo Nordisk; Argenx; Amryt Pharma; Fresenius Medical Care North America; Amarin Corporation; Mylan; Ionis Pharmaceuticals; Abbott Laboratories; Regeneron Pharmaceuticals; Esperion Therapeutics; Ultragenyx Pharmaceutical; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Amgen; Vifor Pharma; Pfizer; Daiichi Sankyo Europe; Silence Therapeutics; Kowa Company; Sanofi","keywords":"Medicine; Familial hypercholesterolemia; Term (time); Plain language; Pediatrics; Internal medicine; Intensive care medicine; Linguistics; Cholesterol","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008545943,0.0004050228,0.002261507,0.0009267468,0.000382575,0.00202634,0.0006060866,0.001665512,0.009424503],"category_scores_gemma":[0.02342016,0.000229291,0.003874623,0.0008868653,0.0005103442,0.001442356,0.0005055245,0.002245608,0.001911779],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001450012,"about_ca_system_score_gemma":0.001787398,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001517113,"about_ca_topic_score_gemma":0.002259693,"domain_scores_codex":[0.9937524,0.002912966,0.001670689,0.0002756948,0.001158175,0.000229987],"domain_scores_gemma":[0.9706189,0.01448459,0.008269027,0.0005871566,0.005372738,0.0006675703],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.0534174,0.001386768,0.03301618,0.0686345,0.008222626,0.001125474,0.0009873438,0.0009434675,0.001774397,0.002308155,0.2225913,0.6055923],"study_design_scores_gemma":[0.0467894,0.05423856,0.2391075,0.09307975,0.0291547,0.003953294,0.0021969,0.00181901,0.003811244,0.005576697,0.5195715,0.0007015732],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"review","genre_gemma":"empirical","genre_scores_codex":[0.1163078,0.718124,0.001980493,0.09441555,0.00661739,0.002439682,0.02814641,0.0001821393,0.03178652],"genre_scores_gemma":[0.4706216,0.3735556,0.003855917,0.09767049,0.01705805,0.004606118,0.01593023,0.0001471591,0.01655477],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.009424503,"threshold_uncertainty_score":0.04519582,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.003289234119944993,"score_gpt":0.2430604286347147,"score_spread":0.2397711945147697,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}